Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_abb55dbccfcc63423146032276d9fdc7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-804 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2020-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a646222517745b5a9c46966e40abf9b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b77fb427bad30a2c52372d9300af31a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8922901afe63711512838465da9c60c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c62b02c42f022286fdb3c6e6f36ab1ad |
publicationDate |
2022-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-114423786-A |
titleOfInvention |
Use of a high-affinity, ligand-blocking, humanized anti-T cell immunoglobulin domain and mucin domain 3 (TIM-3) IgG4 antibody for the treatment of myelofibrosis |
abstract |
The present invention relates to the use of anti-TIM-3 antibody molecules in the treatment of myelofibrosis (MF). The present invention also relates to a pharmaceutical combination comprising a) an anti-TIM-3 antibody molecule, and b) at least one additional therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof. |
priorityDate |
2019-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |